A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease - Test2 - elhamkhani - TriplyDB

A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

http://www.wikidata.org/entity/Q22241518

about

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers Alzheimer's disease as homeostatic responses to age-related myelin breakdown Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer's brains Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61 Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein The toxicity of amyloid β oligomers Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition Protein phosphatases and Alzheimer's disease Mechanisms of synapse and dendrite maintenance and their disruption in psychiatric and neurodegenerative disorders Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases Reversal of long-term dendritic spine alterations in Alzheimer disease models Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake Synapses and Alzheimer's disease Synaptic Cell Adhesion Molecules in Alzheimer's Disease Regulation of the Postsynaptic Compartment of Excitatory Synapses by the Actin Cytoskeleton in Health and Its Disruption in Disease Diabetes Mellitus Induces Alzheimer's Disease Pathology: Histopathological Evidence from Animal Models Amyloid-β Receptors: The Good, the Bad, and the Prion Protein Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics Wnts in action: from synapse formation to synaptic maintenance Abnormal kalirin signaling in neuropsychiatric disorders.TNF-α/NF-κB signaling in the CNS: possible connection to EPHB2 Dementia of the eye: the role of amyloid beta in retinal degeneration Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease Alzheimer's disease and insulin resistance: translating basic science into clinical applications Long non-coding RNA-dependent transcriptional regulation in neuronal development and disease Neuropathological alterations in Alzheimer disease Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease Alzheimer's disease, amyloid peptide and synaptic dysfunction Structural evolution and membrane interactions of Alzheimer's amyloid-beta peptide oligomers: new knowledge from single-molecule fluorescence studies Amyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's disease Molecular mechanisms of dendrite stability Aberrant insulin signaling in Alzheimer's disease: current knowledge Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

P2860

4096d600724109eafdc3935c2558c26d733a6060

P248

Q21146622-B7453A1D-3330-4038-972A-5D6EEADF6E3B Q22251089-8B5A9E5A-36E7-4237-A0E4-130F0CAA1E07 Q22251261-F66B2B85-4094-4CBB-AA70-4D888784DF0A Q24298670-FA5B2150-8E57-48A0-9435-EE1BF3F2E106 Q24329069-EB087A92-F076-4D4C-BE46-CC04C29EC491 Q24338543-C1C72929-D067-4873-8243-CA86C467C64E Q24620404-72A634F3-6E93-4CAE-9D60-22DCF79AC1FC Q24630045-260F5477-46E3-44EA-B123-C6351F4D59FF Q24631757-ACF03ADA-4359-448B-AD58-C64422DB903D Q24631814-CBB57ACE-0C8D-4603-BB75-BD4C9BD60F6B Q24632495-6888B759-FE7A-4067-B689-869CD90D66E0 Q24632757-31EE981B-EC81-46FD-A4D9-3E781E79300D Q24645499-DBD69FF0-7DE0-437C-9139-8D157A74523E Q24650014-545824CE-E2CF-4E20-8360-3AA2B6197164 Q24654995-DA91AFDD-9FFA-4F79-8F53-5C20A9155881 Q24656613-4D66A76F-222C-47F5-A44B-363ED393E37F Q26269868-7440E4A4-1BFF-451B-8947-C906BCA87EA0 Q26744544-7E41B2F5-D3CD-4755-8637-9A51EA3742AC Q26748973-8F58FADF-43D4-4D09-85FF-65D447F5E357 Q26750648-67D9D617-6C56-42DA-8FB1-47CC53C410F4 Q26771532-5F5E1126-3F6C-4EEB-AEC2-B310566446EB Q26781974-8637CFE7-A1B5-49FB-9518-A15A158DF996 Q26822002-6586ACD5-4CCC-4C5C-9435-EACD05A49519 Q26823548-FDF7DCAF-7011-4033-BC72-A6FEB601E146 Q26824648-D3DF1654-9748-43B0-88D4-7A79DCF26CAC Q26828831-8E0D4FA0-7CEA-4C78-B08D-B194985D7331 Q26828978-764B0AD5-9E9D-4CE0-9268-7ED1B3014AC5 Q26853610-EBAF3C7A-41E4-42FD-96C8-663790F4F468 Q26858963-756D47A9-CC83-438F-922D-C85AB6A68CFE Q26866265-5126A3CD-45A8-44E3-BADB-E43F0F64F7CE Q26996487-4B9D84E3-557C-4B78-B545-185D0718424C Q26999388-43CFC632-C0BB-4895-AF33-3CDB314F6458 Q27003314-46103D96-926B-4180-9FD9-D6DAD9EAC89A Q27003841-61C28C9D-A5A2-4221-A27E-302F6583504B Q27005935-4C26B66C-AAA0-4CD8-91C2-469AE0C2954F Q27010584-34042D83-0EDE-4025-95E3-B2FDE836C2EB Q27012950-574E5319-194F-4E12-93B2-139CDAAE076F Q27015653-9716470B-E678-434B-A582-E102C39DDA40 Q27024222-2610E0FD-49B7-4D22-8096-55839CFCA93C Q27025207-EFD4D924-6ED5-42E5-BC5B-881AC5FCC137

P2860

A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

http://www.wikidata.org/entity/Q22241518

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@ast

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@en

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@en-gb

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@nl

type

label

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@ast

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@en

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@en-gb

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@nl

altLabel

Abeta oligomer-induced aberrat ...... ctivity in Alzheimer's disease

@en

prefLabel

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@ast

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@en

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@en-gb

A Oligomer-Induced Aberration ...... ctivity in Alzheimer's Disease

@nl

P1433

Q22241518-4E0BAD42-DC85-48EF-B477-EABF3C206287

P1476

Q22241518-428832CB-CD93-456D-97C8-5E0AA99F2D83

P2093

Q22241518-17B25209-AAA4-4BE9-AA0A-39A666A1EDD0

Q22241518-1E2664DD-F15A-448E-8E1A-623CD9181CDF

Q22241518-467E0925-77B7-4095-8BDB-902C74B8AD70

Q22241518-5BEB7B80-3658-4A19-9430-323AABCA10F1

Q22241518-7049E8EA-F5F4-4426-A1C9-66486EDE8946

Q22241518-7F281251-8E24-4B79-8F04-427E1B61012D

Q22241518-E13A961F-6C59-49BA-A613-1CF461516DF3

Q22241518-E61E7CE8-11D0-4EAD-9AB7-6022BBF8E82A

P304

Q22241518-78A47792-89E7-47D7-82A4-69F42A38FFE4

P31

Q22241518-2233889E-55BC-4A24-822D-C83E34218886

P3181

Q22241518-B64E21D0-FD17-4E41-ABD1-6E7BA21597C8

P356

Q22241518-142DE581-9493-4CA8-89B6-A1C8D9C2C61F

P407

Q22241518-06D84680-3C99-48DC-9343-F9AD2966275C

P433

Q22241518-4944B9A4-51D7-4B44-A1BD-7584FCB98373

P478

Q22241518-6551A5BF-F94D-4809-BA69-DBD2CDE59126

P577

Q22241518-CFA3C86B-31EA-45BA-A84D-5C62C3A1E887

P698

Q22241518-A447E952-A310-4E65-826E-42659D0D96BC

P921

Q22241518-5BAB1E71-3894-4537-ABC0-0D5E5AF9B335

Q22241518-EE7D0A51-9078-4FD8-BD6F-74010736BEF5

P932

Q22241518-CE8580C7-65F9-467E-A774-14E1FE5CF44B

P3181

P356

JNEUROSCI.3501-06.2007

P1433

Journal of Neuroscience

P1476

Abeta oligomer-induced aberrat ...... ctivity in Alzheimer's disease

@en

P2093

Antonio Sanz Clemente

http://www.w3.org/2001/XMLSchema#string

Kirsten L Viola

http://www.w3.org/2001/XMLSchema#string

Margaret Wood

http://www.w3.org/2001/XMLSchema#string

Maria C Buniel

http://www.w3.org/2001/XMLSchema#string

Pascale N Lacor

http://www.w3.org/2001/XMLSchema#string

Paul W Furlow

http://www.w3.org/2001/XMLSchema#string

Pauline T Velasco

http://www.w3.org/2001/XMLSchema#string

William L Klein

http://www.w3.org/2001/XMLSchema#string

P304

796-807

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1262802

http://www.w3.org/2001/XMLSchema#string

P356

10.1523/JNEUROSCI.3501-06.2007

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17251419

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

6672917

http://www.w3.org/2001/XMLSchema#string